+Compare
CNCR
ETF ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Net Assets
11.85M

CNCR Loncar Cancer Immunotherapy ETF Forecast, Technical & Fundamental Analysis

Category Health
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for CNCR with price predictions
07:00 PM EST Dec 04, 2023

CNCR in upward trend: 10-day moving average broke above 50-day moving average on November 27, 2023

The 10-day moving average for CNCR crossed bullishly above the 50-day moving average on November 27, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 22, 2023. You may want to consider a long position or call options on CNCR as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CNCR just turned positive on November 01, 2023. Looking at past instances where CNCR's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

CNCR moved above its 50-day moving average on November 22, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNCR advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 202 cases where CNCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CNCR moved out of overbought territory on December 05, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CNCR broke above its upper Bollinger Band on December 01, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to track the performance, before fees and expenses, of the Range Cancer Therapeutics Index (the “index”). The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.

Market Cap

The average market capitalization across the Loncar Cancer Immunotherapy ETF ETF is 11.4B. The market cap for tickers in the group ranges from 38.19M to 253.86B. MRK holds the highest valuation in this group at 253.86B. The lowest valued company is RAIN at 38.19M.

High and low price notable news

The average weekly price growth across all stocks in the Loncar Cancer Immunotherapy ETF ETF was 8%. For the same ETF, the average monthly price growth was 6%, and the average quarterly price growth was -17%. BMEA experienced the highest price growth at 90%, while REPL experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Loncar Cancer Immunotherapy ETF ETF was -35%. For the same stocks of the ETF, the average monthly volume growth was -53% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 79
Price Growth Rating: 61
SMR Rating: 89
Profit Risk Rating: 89
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ETF Series Solutions615 East Michigan Street, Milwaukee, WisconsinEast Michigan
Phone
(414) 765-5586
Web
N/A
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ANCTF57.57N/A
N/A
Alimentation Couche-Tard Inc.
BTDPY13.35N/A
N/A
Barratt Developments Plc.
IPXHY13.67N/A
N/A
Inpex Corp.
PTHRF0.26N/A
N/A
Pantheon Resources Plc
AWLIF0.06N/A
N/A
AMERIWEST LITHIUM INC

CNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, CNCR has been closely correlated with XBI. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if CNCR jumps, then XBI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CNCR
1D Price
Change %
CNCR100%
-0.79%
XBI - CNCR
88%
Closely correlated
-0.51%
IBB - CNCR
81%
Closely correlated
-0.40%
VHT - CNCR
57%
Loosely correlated
-0.20%
IHI - CNCR
49%
Loosely correlated
-0.89%
XLV - CNCR
47%
Loosely correlated
-0.12%